PARADISE is an ambitious research project in personalised medicine. The millions of people affected by autoimmune conditions have a reduced quality of life. Focusing on ANCA vasculitis as an exemplar relapsing multi-system autoimmune disease, PARADISE will use patient level data to identify the characteristics, or markers, most often linked to relapse events.
Research of this consortium already identified high-potential markers in serum, urine, transcriptomics, and autoantibodies which enabled broad grouping of patients. PARADISE will integrate these markers, delivering a truly 360°approach to relapse prediction.
PARADISE will train clinical decision support tools using the best available longitudinal patient data to identify associated relapse events and thus risk levels.